SUMMARY Thirty-five patients with haemophilia A were studied clinically and serologically between 1971-2 and 1975-6 
The presence of hepatitis B surface antigen (HBsAg) or the development of antibody to hepatitis B core antigen (anti-HBc) or to HBsAg (anti-HBs) are currently the most reliable serological markers of hepatitis B virus (HBV) infection (Hoofnagle et al., 1975) . The first two of these reactions almost invariably indicate ongoing or recent virus replication. The development of the more long-lasting antiHBs (or a significant rise in titre) may indicate either infection or active immunisation with HBsAg. Surveys of the prevalence of anti-HBs in multiply transfused haemophiliacs have confirmed the high rates of exposure to HBsAg in such patients (Peterson et al., 1973; Burrell et al., 1974; Islam and Banatvala, 1976) , although they rarely develop clinical hepatitis (Biggs, 1974) . Universal blood donor screening for HBsAg has substantially reduced but not eliminated post-transfusion hepatitis B infection. For example, in a study of recipients of whole blood transfusion after screening for HBsAg by radioimmunoassay 4 7/1000 tested volunteer donations produced serological evidence of HBsAg exposure (Goldfield et al., 1975) . The continuing risk of HBV infection for haemophiliacs is more difficult to assess.
In a previous study (Burrell et al., 1974) (Burrell et al., 1974) . During this period only one patient suffered from clinical HBsAg-positive hepatitis and subsequently seroconverted to anti-HBs positive (see below). Liver function tests carried out at irregular intervals on most of the patients found no evidence of additional acute infections. All patients except three received varying amounts of replacement therapy during the period. This was given as cryoprecipitate (Pool et al., 1964) , prepared by the Blood Transfusion Service, Edinburgh, from local HBsAgtested donations, and as anti-haemophiliac factor (AHF (Bl6mback, 1958)) or factor VIII concentrate (Newman et al., 1971; James and Wickerhauser, 1972) prepared by the Protein Fractionation Centre of the Scottish National Blood Transfusion Service from donations that were HBsAg tested and forwarded by the various Scottish Blood Transfusion Centres.
HBsAg testing was done initially by countercurrent immunoelectrophoresis and more recently by haemagglutination inhibition (HAI) (Hopkins and Das, 1973) , RPHA (Wellcome Laboratories), or radioimmunoassay (RIA) (Ausria).
Results
At both sampling times all 35 patients were negative for HBsAg by RPHA and 20 (57 %) of them were anti-HBs positive. Twelve patients remained antiHBs positive with unchanging high titres during the study period. No inferences could be made about the effect of therapy on their antibody state. The remaining 23 patients could be grouped as (1) Anti-HBs positive in 1971-2 and negative in 1975-6, (2) AntiHBs negative on both occasions, (3) Anti-HBs negative in 1971-2 and positive in 1975-6, (4) AntiHBs positive on both occasions with a hundredfold or greater increase in antibody titre between the two sampling periods.
In interpreting these findings in terms of exposure to HBsAg it seemed possible that patients in group (2) Antibody to hepatitis B surface antigen in haemophiliacs on long-term therapy with Scottish factor VIII 311 without evidence of exposure may include poor antibody responders or individuals with a short-lived anti-HBs response after contact with positive material. Indeed, the disappearance of detectable anti-HBs between the two sampling times in six patients described here provided clear evidence that such antibody need not persist for life and that surveys of anti-HBs prevalence at one time point will not identify all those who have had HBV infection. In considering our findings we also noted the following factors.
(1) Our figure of 0 3 HBsAg positive donations/ 1000 after HBsAg testing may be lower than the true rate of HBsAg-positive single donations since (a) patients who seroconverted may have received more than one positive unit, (b) positive batches of AHF and factor VIII concentrate may have contained more than one positive donation, and (c) the coexistence of anti-HBs in plasma pools containing HBsAg used to prepare AHF or factor VIII concentrate may have partially neutralised the infectivity (but not necessarily immunogenicity) of the preparation.
(2) The degree of dilution of the HBsAg in one positive donation will have varied significantly according to whether cryoprecipitate (pool size = 1) or factor VIII concentrate (pool size = 800) was used and according to the variable extent of selective concentration or removal of HBsAg and infectious virus during fractionation of the different preparations. Thus the quantities of viral material administered may not be strictly comparable to whole blood transfusion.
(3) Many patients in this survey received repeated treatments with the-same batch of material separated by hours, days, or weeks. HBV infection might be favoured by one large dose whereas active immunisation could be favoured by repeated antigenic stimuli of adequate size. We could not examine the effects of these factors on seroconversion rates.
A Danish study of 36 children with haemophilia A or B receiving replacement therapy from various sources showed serological evidence for 16 exposures to HBsAg in the period (Holsteen et al., 1977 
